Treatment eligibility has expanded throughout sub-Saharan Africa (SSA) in response to the WHO 2015 policy promoting ‘treatment for all’ people living with HIV (PLWH). We evaluated the impact of early vs. late treatment initiation on early gaps in ART usage across two countries in SSA – South Africa (SA) and Uganda (UG) – and identified clinical and psychosocial predictors of losses.
Two cohorts of men and women initiating ART in routine care were prospectively enrolled in Cape Town, SA and southwestern UG: one initiating early (CD4>350 cells/ml) and one initiating late (CD4<200 cells/ml). Participants were seen at 0, 6 and 12 months for socio-behavioral questionnaires and HIV RNA levels. Adherence was monitored in real-time (Wisepill); early gaps were defined as >30 consecutive days without evidence of adherence in the first 6 months of ART. Demographic and clinical factors were compared across groups using chi-square to identify potentially confounding covariates, and logistic regression models were used to estimate predictors of early gaps in ART usage, adjusting for age, gender, employment, education and marital status.
Of the 904 PLWH who were enrolled, 868 (96%) completed follow up, and 670 (77%) were eligible for this analysis (pregnant women were excluded). There were 92 (14%) early gaps in ART use, with a median time to early gap of 80 days (IQR: 45-102). Given the limited number of early gaps in UG (n=21), we explored associated findings in an adjusted model in SA (n=71) (see Table 1). In the adjusted model, PLWH in SA who initiated ART later had double the odds of early gaps in treatment (aOR=2.0, 95%CI: 1.0-4.0). Those who used denial to cope were also at higher odds of early losses (aOR=1.2, 95%CI: 1.0-1.4). Education provided a protective effect against early losses (aOR=0.4, 95%CI: 0.2-0.8). There was no significant difference across age, gender, marital status or employment. Those with early gaps were more likely to have detectable viremia across sites (OR:6.3, p=0.001 in UG vs. OR:2.6, p=0.008 in SA).
Despite global efforts to promote early and enduring treatment, early gaps in ART persist, resulting in higher odds of detectable viremia. These gaps remain significant for key vulnerable populations, specifically those who present late to care, who lack educational opportunities, and who use denial to cope.